Angiochem, GSK to discover therapies for lysosomal storage diseases
Under the partnership deal, Angiochem will develop new compounds (EPiC-enzymes) intended to penetrate the blood-brain barrier (BBB) and restore enzyme function in the central nervous system (CNS). The
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.